U.S. Insulin Prices Rise as Sanofi (France), Novo Nordisk A/S Await Rivals
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sanofi (SAN) raised the U.S. price of its Lantus insulin for a second time this year and Novo Nordisk A/S (NOVOB) may follow suit before an onslaught of generics increases competition in the $35 billion diabetes market. Sanofi raised the U.S. wholesale price of its Lantus vials by almost 15 percent to $16.64 per milliliter and of its Lantus Solostar injection pens by almost 10 percent to $18.38 per milliliter, Jack Cox, a spokesman for Paris-based Sanofi, said in an e-mail. Those increases followed a 10 percent price increase in April for both versions of Lantus, the world’s best-selling diabetes treatment.
Help employers find you! Check out all the jobs and post your resume.
Sanofi (SAN) raised the U.S. price of its Lantus insulin for a second time this year and Novo Nordisk A/S (NOVOB) may follow suit before an onslaught of generics increases competition in the $35 billion diabetes market. Sanofi raised the U.S. wholesale price of its Lantus vials by almost 15 percent to $16.64 per milliliter and of its Lantus Solostar injection pens by almost 10 percent to $18.38 per milliliter, Jack Cox, a spokesman for Paris-based Sanofi, said in an e-mail. Those increases followed a 10 percent price increase in April for both versions of Lantus, the world’s best-selling diabetes treatment.
Help employers find you! Check out all the jobs and post your resume.